Synthesis, evaluation and QSAR studies of 16-(4 and 3,4-substituted) benzylidene androstene derivatives as anticancer agents

Medicinal Chemistry

Volumn 4, Issue 3, 2008, Pages 229-236

  Dubey, S ^a   Kaur, P ^a   Jindal, D P ^b   Satyanarayan, Y D ^a   Piplani, P ^b  

^a A Constituent Unit of KLE Academy of Higher Education Research   (India)

^b PANJAB UNIVERSITY   (India)

Author keywords

Androstane; Anticancer; In vitro activity; QSAR; Steroids

Indexed keywords

16 (3,4 DIMETHOXYBENZYLIDENE) 17 OXO 5 ANDROSTEN 3 BETA OL; 16 (3,4 DIMETHOXYBENZYLIDENE) 17 OXO 5 ANDROSTEN 3 BETA YL ACETATE; 16 (3,4 DIMETHOXYBENZYLIDENE) 3 BETA PYRROLIDINO 5 ANDROSTEN 17 BETA OL; 16 (3,4 DIMETHOXYBENZYLIDENE) 3 BETA PYRROLIDINO 5 ANDROSTEN 17 BETA YL ACETATE; 16 (3,4 DIMETHOXYBENZYLIDENE) 3 BETA PYRROLIDINO 5 ANDROSTEN 3 BETA YL ACETATE; 16 (3,4 DIMETHOXYBENZYLIDENE) 3 PYRROLIDINO 3,5 ANDROSTADIEN 17 ONE; 16 (3,4 DIMETHOXYBENZYLIDENE) 4 ANDROSTENE 3,17 DIONE; 16 (4 METHOXYBENZYLIDENE) 17 OXO 5 ANDROSTEN 3 BETA OL; 16 (4 METHOXYBENZYLIDENE) 17 OXO 5 ANDROSTEN 3 BETA YL ACETATE; 16 (4 METHOXYBENZYLIDENE) 3 BETA PYRROLIDINO 5 ANDROSTEN 17 BETA YL ACETATE; 16 (4 METHOXYBENZYLIDENE) 3 PYRROLIDINO 3,5 ANDROSTADIEN 17 ONE; 16 (4 METHOXYBENZYLIDENE) 4 ANDROSTENE 3,17 DIONE; 16 (4 METHOXYBENZYLIDENE) 5 ANDROSTENE 3 BETA 17 BETA DIOL; 16 (4 METHOXYBENZYLIDENE) 5 ANDROSTENE 3 BETA 17 BETA DIOL DIACETATE; ANTINEOPLASTIC AGENT; BENZYLIDENE ANDROSTENE DERIVATIVE; CYTOTOXIC AGENT;

ALDOL REACTION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; DRUG STRUCTURE; DRUG SYNTHESIS; ESTERIFICATION; HUMAN; HUMAN CELL; MOLECULAR MODEL; OPPENAUER OXIDATION; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION;

ANDROSTENES; ANTINEOPLASTIC AGENTS; BENZYLIDENE COMPOUNDS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 45149099606     PISSN: 15734064     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340608784325133     Document Type: Article

References (14)

1. Azzaoui, K.; Diaz-Perez, M.J.; Zannis-Hadjoupoulos, M.; Price, G.B.; Wainer, I.W. J. Med. Chem., 1998, 41, 1392.
2. Henderson, B.E.; Ross, R.; Bernstein, L. Cancer Res., 1998, 48, 246.
3. Li, J.J.; Li, S.A.; Oberley, T.D. Parsons J.A., Cancer Res., 1995, 55, 4347.
4. Marsh, D.A.; Brodie, H.J.; Garrett, W.; Tsai-Morris, C. H.; Brodie, A.M. J. Med. Chem., 1985, 28, 788.
5. Goss, P.E.; Strasser, K. J. Clin. Oncol., 2001, 19, 881.
6. Bohl, M. In Theoratical Investigation on Steroid Structure and Quantitative Structure Activity Relationships, Bohl, M.; Duax, W.L., Ed.; CRC Press: Boca Raton, FL, 1992, pp. 185-186.
7. Waller, C.L.; Juma, B.W.; Gray, L.E.; Kelce, W.R.; Toxicol. Appl. Pharmacol., 1996, 137, 219.
8. Chattopadhaya, R.; Jindal, D.P.; Minn, M; Gupta, R. Arzneimittel Forschung., 2004, 54, 551.
9. Christiansen, R.G.; Clinton, R.O.; Dean, J. W.; U.S.Pat. 316364, 1964, [Chem. Abstr.1965, 62, 7834].
10. Easthem, J.F.; Taranishi, R. In Organic Synthesis, Adams, R. Ed.; John Wiley and Sons, Inc: New York, 1960, Vol.2, pp. 1-28.
11. Dubey, S.; Piplani, P.; Jindal, D. P. Chem. Biodiv., 2004, 1, 1529.
12. Dubey, S.; Piplani, P.; Jindal, D. P. Ind. J. Chem., 2005, 44B, 2126.
13. Dubey, S; Piplani, P.; Jindal, D. P. Lett. Drug Design Discov., 2005, 2, 537.
14. Draper, N.R.; Smith, H. Applied Regression Analysis, John Wiley & Sons, New York, 1966.